2 results
Approved WMOCompleted
To assess the safety and tolerability profile of LJN452 and to determine the early hepatic response to different doses of LJN452 in patients with phenotypic non-alcoholic steatohepatitis (NASH). Data from this study will be used to support further…
Approved WMORecruiting
Part 1 (phase 1b)Primary:• To observe the safety and tolerability of bemarituzumabSecondary:• To evaluate preliminary antitumor activity• Characterize the pharmacokinetics (PK) of bemarituzumab Part 2 (phase 2)Primary:• To evaluate preliminary…